NBD-14270

NBD-14270, a pyridine analogue, is a potent HIV-1 entry antagonist with an IC50 of 180 nM against 50 HIV-1 Env-pseudotyped viruses. NBD-14270 binds to HIV-1 gp120 and shows potent antiviral activity. NBD-14270 shows low cytotoxicity (CC50>100 μM) [1][2].

Product Specifications

CAS Number

[2411819-82-2]

UNSPSC

12352005

Target

HIV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/nbd-14270.html

Concentration

10mM

Purity

99.53

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

FC(F)(C1=CC=C(N=C1)C2=CC(C)=C(N2)C(N[C@H](C3=NC=C(S3)CO)CN)=O)F

Molecular Formula

C18H18F3N5O2S

Molecular Weight

425.43

References & Citations

[1]Francesca Curreli, et al. Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation. J Med Chem. 2020 Feb 27;63 (4) :1724-1749.|[2]Natalie Losada, et al. HIV-1 gp120 Antagonists Also Inhibit HIV-1 Reverse Transcriptase by Bridging the NNRTI and NRTI Sites. J Med Chem. 2021 Nov 25;64 (22) :16530-16540.